You are here

iptacopan

Novartis unveils promising Fabhalta data for C3 glomerulopathy indication

Medical Marketing and Media

Tue, 12/12/23 - 09:56 am

clinical trials

C3 glomerulopathy

Novartis receives FDA approval for Fabhalta to treat PNH in adults

Pharmaceutical Business Review

Wed, 12/6/23 - 10:25 am

paroxysmal nocturnal hemoglobinuria

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Clinical Trials Arena

Mon, 10/2/23 - 10:14 am

clinical trials

IgA nephropathy

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Fri, 06/9/23 - 10:01 am

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Clinical Trials Arena

Thu, 04/27/23 - 10:30 am

clinical trials

Could This Be Novartis' Next Blockbuster Medicine?

Motley Fool

Fri, 01/27/23 - 10:27 am

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Fierce Biotech

Tue, 12/13/22 - 10:28 am

Novartis' iptacopan meets PhIII test in fight against rare blood disease

Endpoints

Thu, 12/8/22 - 10:37 am

clinical trials

paroxysmal nocturnal hemoglobinuria

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

Mon, 10/24/22 - 11:17 pm

clinical trials

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Pharmaphorum

Mon, 10/24/22 - 10:47 am

clinical trials

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Pharmaforum

Fri, 11/5/21 - 09:54 am

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

Pharmaforum

Sat, 06/12/21 - 10:26 pm

clinical trials

Novartis' Most Advanced Kidney Compound Shows Promise in C3G

BioSpace

Mon, 10/26/20 - 11:11 am

clinical trials